IACTA Pharmaceuticals is focused on advancing ophthalmic care through innovative research and development, particularly targeting significant therapeutic areas such as ocular pain and dry eye disease. The company aims to bridge the gap between small research firms and large pharmaceutical companies, which often limits the development of promising research ideas. By leveraging a dedicated team with extensive experience in ophthalmology and pharmaceutical startups, IACTA is committed to transforming groundbreaking technologies into effective eye care products that address unmet medical needs in the growing global eye care market.

One of the key technologies being explored by IACTA is nano-encapsulation, which enhances the delivery of drugs to ocular tissues. This cutting-edge approach allows for improved therapeutic efficacy and patient outcomes. Additionally, IACTA is collaborating with other industry leaders to develop novel treatment options, such as the DENKI SYK Kinase Inhibitor, which targets ocular pain—a market with significant unmet demand. Through these innovative technologies and strategic partnerships, IACTA Pharmaceuticals is poised to make a meaningful impact in the field of ophthalmology.

United States

Our goal is to vastly improve patient care and outcomes by bringing innovative eye care technology to the healthcare industry. We want to significantly advance the efficacy and safety of existing eye care drugs while developing new ophthalmic drugs that address many unmet medical needs.

Through our unique and extensive partnerships, we are able to identify and launch new technologies into beneficial treatments that can help many patients worldwide.

IACTA Pharmaceuticals

Company Details